The plan calls for 45 thousand jobs at full buildout. Already there is a $10 Billion dollar annual economic impact in a single square mile….
Find out what's happening on campus and across the industry.
Read Fitzsimons Innovation Community news, industry highlights, editorials, and innovation updates happening weekly on our campus.
Explore how Atara's investigational EBV T-cell platform-based therapies target cancer and autoimmune diseases are manufactured.
Rather than just redirecting flow, implantations provide therapy to heart cells and drive new tissue
Ceria Therapeutics, Inc. Awarded a $300,000 SBIR Grant to Advance Development of a Novel Treatment of Non-Healing Diabetic Foot Ulcers
Ceria Therapeutics, Inc. (Ceria), a Colorado-based biotech startup focusing on the development of novel therapeutics to address several inflammatory diseases, today announced the company has received a second Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). This award is directed to development of CTX-001 for the treatment of non-healing diabetic foot ulcers (DFUs).
University of Colorado faculty this year attracted $1.46 billion in sponsored research funding and gifts supporting research. The support powers wide-ranging discovery and impact, ultimately benefiting Colorado, the nation and the world.
Foresight Diagnostics, Inc, a leader in cancer diagnostics and cancer relapse testing, announced today that the U.S. Patent and Trademark Office (USPTO) has granted the company patent No. 11,447,833 for the detection of minimal residual disease (MRD) using its personalized phased variant detection platform. "We are pleased that the USPTO has recognized the novel nature of our proprietary technology and are excited about the impact we believe this technology will have on the lives of cancer patients," said Dr. Jake Chabon, Ph.D., Chief Executive Officer of Foresight Diagnostics.
Ventria Bioscience Wins Exclusion Order Against Infringing and Mislabled Products From Wuhan Healthgen
"Ventria’s success in excluding unfairly traded imports secures its ability to continue to invest in the next generation of plant biotechnology innovation"
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Atara Biotherapeutics and their partner Pierre Fabre Group announce that the European Medicines Agency's CHMP issued a positive opinion for their investigational therapy to treat adult and pediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease.